Zobrazeno 1 - 10
of 87
pro vyhledávání: '"Javier Chaparro"'
Autor:
Changhua Ji, Bing Kuang, Bernard S Buetow, Allison Vitsky, Yuanming Xu, Tzu-Hsuan Huang, Javier Chaparro-Riggers, Eugenia Kraynov, Diane Matsumoto
Publikováno v:
PLoS ONE, Vol 19, Iss 2, p e0298240 (2024)
PF-07209960 is a novel bispecific fusion protein composed of an anti-PD-1 antibody and engineered IL-15 cytokine mutein with reduced binding affinity to its receptors. The pharmacokinetics (PK), pharmacodynamics (PD), and toxicity of PF-07209960 were
Externí odkaz:
https://doaj.org/article/c39ae2f51f884dbb9d5bbfa5463a5364
Publikováno v:
Ingeniería Investigación y Desarrollo, Vol 23, Iss 2 (2023)
Los residuos sólidos municipales (MSW) por sus siglas en inglés, son aquellos residuos generados por la población en las ciudades, producto de las actividades residenciales, institucionales y comerciales en cada municipio, los cuales se consideran
Externí odkaz:
https://doaj.org/article/1c0de94e224d4dc6ab85a9193b1337ec
Autor:
Javier Chaparro, Juan-Manuel Urbina
Publikováno v:
Chemical Engineering Transactions, Vol 93 (2022)
Acid-catalysed Fischer esterification of fatty acids with methanol as a reagent and solvent is regularly used to prepare long chain alkyl methyl esters. Transesterification of palm oil in basic media using methanol is also a synthesis route to prepar
Externí odkaz:
https://doaj.org/article/f2d21fd58ef943edaffb50bba9a0cd69
Autor:
Spencer Park, Edward Pascua, Kevin C. Lindquist, Christopher Kimberlin, Xiaodi Deng, Yvonne S. L. Mak, Zea Melton, Theodore O. Johnson, Regina Lin, Bijan Boldajipour, Robert T. Abraham, Jaume Pons, Barbra Johnson Sasu, Thomas J. Van Blarcom, Javier Chaparro-Riggers
Publikováno v:
Nature Communications, Vol 12, Iss 1, Pp 1-10 (2021)
Many next-generation antibody therapeutics have enhanced potency but the risk of adverse events. Here the authors develop a conditionally activated, single-module CAR.
Externí odkaz:
https://doaj.org/article/a6c74f8c5d424b06a2dbc5aa3382a4ec
Autor:
Shahram Salek-Ardakani, Wenjing Yang, Sheng Ding, Shih-Hsun Chen, Jessica Stanfield, Nadia Kurd, Ryan Llewellyn, Jonathan Heyen, Carole Wang, Zea Melton, Javier Chaparro-Riggers, Pawel Dominik, Kevin Lindquist, Thomas Van Blarcom
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss Suppl 2 (2021)
Externí odkaz:
https://doaj.org/article/1f019c3519b849a08123380e84c26521
Autor:
Shahram Salek-Ardakani, Wenjing Yang, Sheng Ding, Shih-Hsun Chen, Pawel K Dominik, Jessica Stanfield, Nadia Kurd, Ryan Llewellyn, Jonathan Heyen, Carole Wang, Zea Melton, Thomas Van Blarcom, Kevin C Lindquist, Javier Chaparro-Riggers
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss 10 (2021)
Externí odkaz:
https://doaj.org/article/3920fe53e43c44dd89bb0d4a1c33ff53
Autor:
Wei Chen, Fan Yang, Carole Wang, Jatin Narula, Edward Pascua, Irene Ni, Sheng Ding, Xiaodi Deng, Matthew Ling-Hon Chu, Amber Pham, Xiaoyue Jiang, Kevin C. Lindquist, Patrick J. Doonan, Tom Van Blarcom, Yik Andy Yeung, Javier Chaparro-Riggers
Publikováno v:
mAbs, Vol 13, Iss 1 (2021)
T-cell engaging biologics is a class of novel and promising immune-oncology compounds that leverage the immune system to eradicate cancer. Here, we compared and contrasted a bispecific diabody-Fc format, which displays a relatively short antigen-bind
Externí odkaz:
https://doaj.org/article/689b1a83bc0d495ead97d93c01362efb
Autor:
Wei Chen, Yan Qu, Shahram Salek-Ardakani, Graham Thomas, Jonathan Heyen, Javier Chaparro-Riggers, Caroline Bonnans, Wenqian He, Bernard Buetow, Min Liao, Breanna Jung, Smitha Pillai, Diane Matsumoto
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 8, Iss 1 (2020)
Background CD40 is a compelling target for cancer immunotherapy, however, attempts to successfully target this pathway have consistently been hampered by dose-limiting toxicity issues in the clinic that prevents the administration of efficacious dose
Externí odkaz:
https://doaj.org/article/ae636e3f380f4f3ea16f7ab81207e542
Autor:
S. Michael Chin, Christopher R. Kimberlin, Zygy Roe-Zurz, Pamela Zhang, Allison Xu, Sindy Liao-Chan, Debasish Sen, Andrew R. Nager, Nicole Schirle Oakdale, Colleen Brown, Feng Wang, Yuting Yang, Kevin Lindquist, Yik Andy Yeung, Shahram Salek-Ardakani, Javier Chaparro-Riggers
Publikováno v:
Nature Communications, Vol 9, Iss 1, Pp 1-13 (2018)
The costimulatory T-cell receptor 4-1BB is an immuno-oncology target. Here the authors present the ligand bound 4-1BB receptor crystal structure in addition to the structures of 4-1BB bound with two therapeutic antibodies and verify the antibody bind
Externí odkaz:
https://doaj.org/article/11f466e447544959a4ac278b485a238c
Autor:
Pamela Zhang, Guang Huan Tu, Jie Wei, Pamela Santiago, Lance R. Larrabee, Sindy Liao-Chan, Tina Mistry, Matthew Ling-Hon Chu, Tao Sai, Kevin Lindquist, Hua Long, Javier Chaparro-Riggers, Shahram Salek-Ardakani, Yik Andy Yeung
Publikováno v:
Cell Reports, Vol 27, Iss 11, Pp 3117-3123.e5 (2019)
Summary: Agonistic antibodies targeting the tumor necrosis factor (TNF) superfamily of co-stimulatory receptors (TNFRSF) are progressing through various stages of clinical development for cancer treatment, but the desired and defining features of the
Externí odkaz:
https://doaj.org/article/44cb539f22be4485ababb5654bc38b0f